Overview |
bs-12334R |
GCNT1 Polyclonal Antibody |
WB, ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC), ICC |
Human, Mouse |
Rat, Dog, Cow, Sheep |
Specifications |
Unconjugated |
Rabbit |
KLH conjugated synthetic peptide derived from human GCNT1 |
201-260/428 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
Target |
2650 |
Cytoplasm, Cell membrane |
3-galactosyl-O-glycosyl-glycoprotein beta-1; 6-N-acetylglucosaminyltransferase; Beta-1; Beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase; C2GNT; C2GNT L; C2GNT1; C2GnTL; Core 2 branching enzyme; Core 2 GNT; Core 2-branching enzyme; Core2 GlcNAc transferase; Core2-GlcNAc-transferase; GCNT 1; GCNT 1; GCNT1; GCNT1_HUMAN; glucosaminyl N-acetyl transferase 1 core 2; NACGT2. |
GCNT1 is expressed in a variety of cell types, including lymphocytes and mucin-producing cells. Specifically, GCNT1 expression in leukocytes regulates the synthesis of core 2 O-glycans that carry sialyl-Lewis x (sLex) oligosaccharides, which confer high affinity binding to Selectins. Downregulation of Selectin ligand expression levels has been shown to inhibit tissue infiltration. Therefore, GCNT1 represents a potential drug target for the treatment of inflammatory disorders and other pathologies involving Selectins. |
Application Dilution |
WB |
1:300-5000 |
ELISA |
1:500-1000 |
IHC-P |
1:200-400 |
IHC-F |
1:100-500 |
IF(IHC-P) |
1:50-200 |
IF(IHC-F) |
1:50-200 |
IF(ICC) |
1:50-200 |
ICC |
1:100-500 |